Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

• ClinicalTrials.gov Identifier: NCT01072370
• Recruitment Status: Withdrawn
• First Posted: February 22, 2010
• Last Update Posted: October 7, 2022
• Sponsor: Augusta University
• Information provided by (Responsible Party): James E. Carroll, Augusta University

Study Description

Brief Summary:

The purpose of this study is to test the safety and effectiveness of a cord blood infusion in children who have motor disability due to cerebral palsy (CP). The subjects will be children whose parents have saved their infant's cord blood, who have non-progressive motor disability, and whose parents intend to have a cord blood infusion.

Condition or disease	Intervention/treatment	Phase
Cerebral Palsy	Biological: Cord Blood Infusion; Biological: Intravenous Sham	Phase 1; Phase 2

Detailed Description:

The purpose of this study is to conduct an observer-blinded crossover investigation of the safety and efficacy of autologous cord blood infusion in children who demonstrate non-progressive motor disability due to brain dysfunction (commonly called cerebral palsy) and who do not have an apparent disorder of brain development or obstructive hydrocephalus. The degree of delay in motor development will be such that the children are unable to sit independently by 12 months of age or unable to walk independently by 18 months of age. However, because the diagnosis is one of exclusion, we will enroll patients only after they have reached two years of age. By this age, it is likely other conditions would be excluded. As the Gross Motor Function Classification System (GMFCS) was developed for children up to 12 years of age, the maximum age of recruitment will be 12 years. Any level of cerebral palsy severity will be allowed. The subjects will be children whose parents have saved their infants cord blood, who have clinical evidence of a non-progressive motor disability, and whose parents intend to have a cord blood infusion.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Placebo-Controlled, Observer-Blinded, Crossover Study to Evaluate the Safety and Effectiveness of a Single, Autologous, Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children
• Study Start Date: January 2010
• Actual Primary Completion Date: February 28, 2019
• Actual Study Completion Date: February 28, 2019

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Treatment Group 1	Biological: Cord Blood Infusion; red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion; Other Name: Stem cell infusion
Sham Comparator: Treatment Group 2	Biological: Intravenous Sham; intravenous infusion of 5% dextrose, ¼ normal saline solution; Other Name: Placebo

Outcome Measures

Primary Outcome Measures :

1. Confirm the safety of autologous cord blood infusion in children with cerebral palsy by repeated follow-up over one year with clinical and laboratory evaluations. [ Time Frame: 1 year ]

Secondary Outcome Measures :

1. Confirm the efficacy of autologous cord blood infusion in children with cerebral palsy using patient questionnaire and standardized Gross Motor Function Measure evaluation. [ Time Frame: 3-4 months ]

Eligibility Criteria

• Ages Eligible for Study: 1 Year to 12 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Must be more than 1 year of age and less than 12 years of age at the time of screening for inclusion in the study.
• Clinical evidence of a non-progressive motor disability due to brain dysfunction. The subjects will not have the ability to sit independently by one year of age or the ability to walk by 18 months of age.
• Have stored umbilical cord blood with Cord Blood Registry (CBR) that meets all selection and testing criteria.
• Willing to comply with all study procedures.
• The nucleated cells available in the cord blood sample stored at CBR must exceed 1 X 107 cells per kg body weight. (Note: Because cord blood collection has been in process for about 16 years but widely for far less than that period, the age of most subjects likely will be considerably less than 12 years of age. Due to the amount due of cord blood available for most subjects, the body weight of subjects usually will not exceed 25 kg).
• The patients must be seizure-free or seizures adequately controlled. If there is a suspicion of seizures and EEG should be done prior to inclusion.

Exclusion Criteria:

• Have complicating medical issues that would interfere with blood drawing, such as venous access so limited that success is unlikely
• Presence of obstructive hydrocephalus.
• Presence of progressive neurological disease.
• Presence of significant defect of brain development, such as schizencephaly or agenesis of corpus callosum
• Presence of known chromosomal anomaly
• Presence of major congenital anomaly
• Severe intrauterine growth restriction (birth weight less than 1800 grams)
• Cord blood viability <60%
• Positive infectious disease markers from mother's blood or cord blood at the time of collection.
• Evidence of illness on planned infusion date (such as but not limited to fever >38.5, vomiting, diarrhea, wheezing, or crackles)
• Pregnancy
• Use of immunosuppressive drugs
• Evidence of known genetic disorder
• Impaired hepatic or renal function

Contacts and Locations

Locations

United States, Georgia

Augusta University

Augusta, Georgia, United States, 30912

Sponsors and Collaborators

Augusta University

Investigators

• Study Chair: James E Carroll, M.D.; Augusta University

More Information

Additional Information:

Augusta University 

Cord Blood Registry 

• Responsible Party: James E. Carroll, Professor and Chief, Child Neurology, Augusta University
• ClinicalTrials.gov Identifier: NCT01072370
• Other Study ID Numbers: ACBSC09
• First Posted: February 22, 2010
• Last Update Posted: October 7, 2022
• Last Verified: October 2022

Keywords provided by James E. Carroll, Augusta University:

Umbilical Cord Blood; Stem Cells; Autologous Blood Transfusion; Cerebral Palsy

Additional relevant MeSH terms:

Paralysis; Cerebral Palsy; Neurologic Manifestations; Nervous System Diseases; Brain Damage, Chronic; Brain Diseases; Central Nervous System Diseases